FLEX LTD. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that FLEX LTD. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2010 | Mar 31, 2011 | $6.86B | May 23, 2011 |
| FY2010 | Dec 31, 2010 | $7.83B | May 23, 2011 |
| FY2010 | Oct 1, 2010 | $7.42B | May 23, 2011 |
| FY2010 | Jul 2, 2010 | $6.57B | May 23, 2011 |
| FY2010 | Mar 31, 2010 | $5.94B | May 23, 2011 |
| FY2010 | Dec 31, 2009 | $6.56B | May 23, 2011 |
| FY2010 | Oct 2, 2009 | $5.83B | May 23, 2011 |
| FY2010 | Jul 3, 2009 | $5.78B | May 23, 2011 |
| FY2009 | Mar 31, 2009 | $30.95B | May 24, 2010 |
| FY2009 | Mar 31, 2008 | $27.56B | May 24, 2010 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $6.40B | May 21, 2025 |
| FY2025 | Dec 31, 2024 | $6.56B | May 21, 2025 |
| FY2025 | Sep 27, 2024 | $6.55B | May 21, 2025 |
| FY2025 | Jun 28, 2024 | $6.31B | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $6.17B | May 21, 2025 |
| FY2025 | Dec 31, 2023 | $6.42B | May 21, 2025 |
| FY2025 | Sep 29, 2023 | $6.93B | May 21, 2025 |
| FY2025 | Jun 30, 2023 | $6.89B | May 21, 2025 |
| FY2024 | Mar 31, 2023 | $6.98B | May 17, 2024 |
| FY2024 | Dec 31, 2022 | $7.25B | May 17, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Mar 31, 2018 | $6.41B | Jun 14, 2018 |
| FY2018 | Dec 31, 2017 | $6.75B | Jun 14, 2018 |
| FY2018 | Sep 29, 2017 | $6.27B | Jun 14, 2018 |
| FY2018 | Jun 30, 2017 | $6.01B | Jun 14, 2018 |
| FY2018 | Mar 31, 2017 | $5.86B | Jun 14, 2018 |
| FY2018 | Dec 31, 2016 | $6.11B | Jun 14, 2018 |
| FY2018 | Sep 30, 2016 | $6.01B | Jun 14, 2018 |
| FY2018 | Jul 1, 2016 | $5.88B | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | $5.77B | May 16, 2017 |
| FY2017 | Dec 31, 2015 | $6.76B | May 16, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $563.00M | May 21, 2025 |
| FY2025 | Dec 31, 2024 | $594.00M | May 21, 2025 |
| FY2025 | Sep 27, 2024 | $531.00M | May 21, 2025 |
| FY2025 | Jun 28, 2024 | $471.00M | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $437.00M | May 21, 2025 |
| FY2025 | Dec 31, 2023 | $433.00M | May 21, 2025 |
| FY2025 | Sep 29, 2023 | $519.00M | May 21, 2025 |
| FY2025 | Jun 30, 2023 | $476.00M | May 21, 2025 |
| FY2024 | Mar 31, 2023 | $465.00M | May 17, 2024 |
| FY2024 | Dec 31, 2022 | $499.00M | May 17, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $222.00M | May 21, 2025 |
| FY2025 | Dec 31, 2024 | $263.00M | May 21, 2025 |
| FY2025 | Sep 27, 2024 | $214.00M | May 21, 2025 |
| FY2025 | Jun 28, 2024 | $139.00M | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $395.00M | May 21, 2025 |
| FY2025 | Dec 31, 2023 | $197.00M | May 21, 2025 |
| FY2025 | Sep 29, 2023 | $228.00M | May 21, 2025 |
| FY2025 | Jun 30, 2023 | $186.00M | May 21, 2025 |
| FY2024 | Mar 31, 2023 | $142.00M | May 17, 2024 |
| FY2024 | Dec 31, 2022 | $230.00M | May 17, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $305.00M | May 21, 2025 |
| FY2025 | Dec 31, 2024 | $334.00M | May 21, 2025 |
| FY2025 | Sep 27, 2024 | $297.00M | May 21, 2025 |
| FY2025 | Jun 28, 2024 | $233.00M | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $159.00M | May 21, 2025 |
| FY2025 | Dec 31, 2023 | $198.00M | May 21, 2025 |
| FY2025 | Sep 29, 2023 | $281.00M | May 21, 2025 |
| FY2025 | Jun 30, 2023 | $215.00M | May 21, 2025 |
| FY2024 | Mar 31, 2023 | $223.00M | May 17, 2024 |
| FY2024 | Dec 31, 2022 | $259.00M | May 17, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Mar 31, 2018 | $78.20M | Jun 14, 2018 |
| FY2018 | Mar 31, 2017 | $65.60M | Jun 14, 2018 |
| FY2018 | Mar 31, 2016 | $61.00M | Jun 14, 2018 |
| FY2017 | Mar 31, 2015 | $26.30M | May 16, 2017 |
| FY2016 | Mar 31, 2014 | $30.00M | May 20, 2016 |
| FY2013 | Mar 31, 2012 | $78.90M | May 20, 2014 |
| FY2012 | Mar 31, 2011 | $46.50M | May 28, 2013 |
| FY2011 | Mar 31, 2010 | $13.30M | May 29, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $904.00M | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $922.00M | May 21, 2025 |
| FY2025 | Mar 31, 2023 | $874.00M | May 21, 2025 |
| FY2024 | Mar 31, 2022 | $830.00M | May 17, 2024 |
| FY2023 | Mar 31, 2021 | $817.00M | May 19, 2023 |
| FY2022 | Mar 31, 2020 | $834.00M | May 20, 2022 |
| FY2021 | Mar 31, 2019 | $953.00M | May 19, 2021 |
| FY2020 | Mar 31, 2018 | $1.02B | May 28, 2020 |
| FY2019 | Mar 31, 2017 | $937.34M | May 21, 2019 |
| FY2018 | Mar 31, 2016 | $954.89M | Jun 14, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.51B | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $1.33B | May 21, 2025 |
| FY2025 | Mar 31, 2023 | $950.00M | May 21, 2025 |
| FY2024 | Mar 31, 2022 | $1.02B | May 17, 2024 |
| FY2023 | Mar 31, 2021 | $144.00M | May 19, 2023 |
| FY2022 | Mar 31, 2020 | ($1.53B) | May 20, 2022 |
| FY2021 | Mar 31, 2019 | ($2.97B) | May 19, 2021 |
| FY2020 | Mar 31, 2018 | ($3.87B) | May 28, 2020 |
| FY2019 | Mar 31, 2017 | ($3.82B) | May 21, 2019 |
| FY2018 | Mar 31, 2016 | $1.14B | Jun 14, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $438.00M | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $530.00M | May 21, 2025 |
| FY2025 | Mar 31, 2023 | $635.00M | May 21, 2025 |
| FY2024 | Mar 31, 2022 | $443.00M | May 17, 2024 |
| FY2023 | Mar 31, 2021 | $351.00M | May 19, 2023 |
| FY2022 | Mar 31, 2020 | $462.00M | May 20, 2022 |
| FY2021 | Mar 31, 2019 | $726.00M | May 19, 2021 |
| FY2020 | Mar 31, 2018 | $562.00M | May 28, 2020 |
| FY2019 | Mar 31, 2017 | $525.11M | May 21, 2019 |
| FY2018 | Mar 31, 2016 | $510.63M | Jun 14, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $18.38B | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $18.26B | May 21, 2025 |
| FY2024 | Mar 31, 2023 | $21.41B | May 17, 2024 |
| FY2023 | Mar 31, 2022 | $19.33B | May 19, 2023 |
| FY2022 | Mar 31, 2021 | $15.84B | May 20, 2022 |
| FY2021 | Mar 31, 2020 | $13.69B | May 19, 2021 |
| FY2020 | Mar 31, 2019 | $13.50B | May 28, 2020 |
| FY2019 | Mar 31, 2018 | $13.72B | May 21, 2019 |
| FY2018 | Mar 31, 2017 | $12.59B | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | $12.38B | May 16, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $13.38B | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $12.93B | May 21, 2025 |
| FY2024 | Mar 31, 2023 | $15.70B | May 17, 2024 |
| FY2023 | Mar 31, 2022 | $15.12B | May 19, 2023 |
| FY2022 | Mar 31, 2021 | $12.40B | May 20, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $5.00B | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $5.33B | May 21, 2025 |
| FY2024 | Mar 31, 2023 | $5.35B | May 17, 2024 |
| FY2023 | Mar 31, 2022 | $4.13B | May 19, 2023 |
| FY2018 | Mar 31, 2018 | $3.02B | Jun 14, 2018 |
| FY2018 | Mar 31, 2017 | $2.64B | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | $2.57B | May 16, 2017 |
| FY2016 | Mar 31, 2015 | $2.36B | May 20, 2016 |
| FY2015 | Mar 31, 2014 | $2.16B | May 21, 2015 |
| FY2013 | Mar 31, 2013 | $2.25B | May 20, 2014 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.34B | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $1.14B | May 21, 2025 |
| FY2025 | Mar 31, 2023 | $1.14B | May 21, 2025 |
| FY2024 | Mar 31, 2022 | $1.14B | May 17, 2024 |
| FY2023 | Mar 31, 2021 | $1.09B | May 19, 2023 |
| FY2022 | Mar 31, 2020 | $1.07B | May 20, 2022 |
| FY2021 | Mar 31, 2019 | $1.07B | May 19, 2021 |
| FY2019 | Mar 31, 2018 | $1.12B | May 21, 2019 |
| FY2018 | Mar 31, 2017 | $984.87M | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | $942.07M | May 16, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.28B | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $446.00M | May 21, 2025 |
| FY2024 | Mar 31, 2023 | ($560.00M) | May 17, 2024 |
| FY2023 | Mar 31, 2022 | ($1.35B) | May 19, 2023 |
| FY2022 | Mar 31, 2021 | ($2.29B) | May 20, 2022 |
| FY2021 | Mar 31, 2020 | ($2.90B) | May 19, 2021 |
| FY2020 | Mar 31, 2019 | ($3.01B) | May 28, 2020 |
| FY2019 | Mar 31, 2018 | ($3.14B) | May 21, 2019 |
| FY2018 | Mar 31, 2017 | ($3.57B) | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | ($3.89B) | May 16, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $2.29B | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $2.47B | May 21, 2025 |
| FY2024 | Mar 31, 2023 | $3.16B | May 17, 2024 |
| FY2023 | Mar 31, 2022 | $2.96B | May 19, 2023 |
| FY2022 | Mar 31, 2021 | $2.64B | May 20, 2022 |
| FY2021 | Mar 31, 2020 | $1.92B | May 19, 2021 |
| FY2020 | Mar 31, 2019 | $1.70B | May 28, 2020 |
| FY2019 | Mar 31, 2018 | $1.47B | May 21, 2019 |
| FY2018 | Mar 31, 2017 | $1.83B | Jun 14, 2018 |
| FY2018 | Mar 31, 2016 | $1.61B | Jun 14, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $3.69B | May 21, 2025 |
| FY2025 | Mar 31, 2024 | $3.26B | May 21, 2025 |
| FY2024 | Mar 31, 2023 | $3.69B | May 17, 2024 |
| FY2023 | Mar 31, 2022 | $4.20B | May 19, 2023 |
| FY2021 | Mar 31, 2021 | $3.80B | May 19, 2021 |
| FY2020 | Mar 31, 2020 | $2.85B | May 28, 2020 |
| FY2019 | Mar 31, 2019 | $3.07B | May 21, 2019 |
| FY2018 | Mar 31, 2018 | $2.95B | Jun 14, 2018 |
| FY2017 | Mar 31, 2017 | $2.97B | May 16, 2017 |
| FY2016 | Mar 31, 2016 | $2.79B | May 20, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | May 21, 2025 |
| FY2025 | Dec 31, 2024 | 0 | May 21, 2025 |
| FY2025 | Sep 27, 2024 | 0 | May 21, 2025 |
| FY2025 | Jun 28, 2024 | 0 | May 21, 2025 |
| FY2025 | Mar 31, 2024 | 0 | May 21, 2025 |
| FY2025 | Dec 31, 2023 | 0 | May 21, 2025 |
| FY2025 | Sep 29, 2023 | 0 | May 21, 2025 |
| FY2025 | Jun 30, 2023 | 0 | May 21, 2025 |
| FY2024 | Mar 31, 2023 | 0 | May 17, 2024 |
| FY2024 | Dec 31, 2022 | 0 | May 17, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 0 | May 21, 2025 |
| FY2025 | Dec 31, 2024 | 0 | May 21, 2025 |
| FY2025 | Sep 27, 2024 | 0 | May 21, 2025 |
| FY2025 | Jun 28, 2024 | 0 | May 21, 2025 |
| FY2025 | Mar 31, 2024 | 0 | May 21, 2025 |
| FY2025 | Dec 31, 2023 | 0 | May 21, 2025 |
| FY2025 | Sep 29, 2023 | 0 | May 21, 2025 |
| FY2025 | Jun 30, 2023 | 0 | May 21, 2025 |
| FY2024 | Mar 31, 2023 | 0 | May 17, 2024 |
| FY2024 | Dec 31, 2022 | 0 | May 17, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 377.82M | May 21, 2025 |
| FY2025 | Mar 31, 2024 | 408.10M | May 21, 2025 |
| FY2024 | Mar 31, 2023 | 450.12M | May 17, 2024 |
| FY2023 | Mar 31, 2022 | 460.56M | May 19, 2023 |
| FY2022 | Mar 31, 2021 | 492.57M | May 20, 2022 |
| FY2021 | Mar 31, 2020 | 497.43M | May 19, 2021 |
| FY2020 | Mar 31, 2019 | 516.55M | May 28, 2020 |
| FY2019 | Mar 31, 2018 | 528.08M | May 21, 2019 |
| FY2018 | Mar 31, 2017 | 531.29M | Jun 14, 2018 |
| FY2017 | Mar 31, 2016 | 544.82M | May 16, 2017 |